Jun 11 |
Pharvaris Announces Annual Meeting of Shareholders
|
Jun 4 |
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
|
May 13 |
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
|
May 9 |
Pharvaris reports Q1 results
|
May 8 |
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
|
Apr 12 |
Pharvaris files for automatic mixed securities shelf
|
Apr 12 |
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
|
Apr 10 |
Pharvaris reports Q4 results
|
Apr 10 |
Pharvaris appoints David Nassif as chief financial officer
|
Apr 10 |
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|